Literature DB >> 18997044

Incremental value of 131I SPECT/CT in the management of patients with differentiated thyroid carcinoma.

Libo Chen1, Quanyong Luo, Yan Shen, Yongli Yu, Zhibin Yuan, Hankui Lu, Ruisen Zhu.   

Abstract

UNLABELLED: (131)I whole-body scintigraphy (WBS) is a highly sensitive method for the detection of differentiated thyroid tumors and metastases. However, a lack of anatomic landmarks and the physiologic accumulation of the tracer complicate interpretation of the images. This prospective study was designed to evaluate the incremental value of (131)I SPECT/CT over planar WBS in the management of patients with differentiated thyroid carcinoma (DTC).
METHODS: Planar imaging was performed on 66 consecutive DTC patients who were considered to have locally advanced or metastatic disease after total or nearly total thyroidectomy. SPECT/CT was added for patients whose planar findings were inconclusive. The planar images were interpreted by 2 experienced nuclear medicine physicians. Interpretation of the SPECT/CT images was a consensus opinion of one of the nuclear medicine physicians and an experienced radiologist. Fusion images were considered to improve image interpretation when they better localized sites of increased (131)I uptake. The final diagnosis was verified by pathologic findings, other imaging modalities, and clinical follow-up. Both site-based and patient-based analyses were performed, and the impact of SPECT/CT results on therapeutic strategy was assessed.
RESULTS: A total of 232 foci were observed by (131)I WBS, including 33.2% of foci localized in the thyroid bed, 62.1% due to malignant lesions, and 4.7% caused by nonthyroidal physiologic or benign uptake or a contaminant. Overall, 37 SPECT/CT studies were performed on 23 patients, whose planar images showed 81 inconclusive lesions. Precise localization and characterization of (131)I-avid foci were achieved through (131)I SPECT/CT in 69 (85.2%) and 67 (82.7%) of the 81 foci, respectively. Fusion images were considered to be of benefit in 17 (73.9%) of 23 patients. The therapeutic strategy was changed in 8 (47.1%) of 17 patients. Uncommon metastatic lesions were found in 9 (13.6%) of 66 patients with regard to SPECT/CT fusion images.
CONCLUSION: Fusion of SPECT and CT images was of incremental value over WBS in increasing diagnostic accuracy, reducing pitfalls, and modifying therapeutic strategies in 73.9% of DTC patients. As SPECT/CT techniques emerge, (131)I SPECT/CT may demonstrate higher value than WBS in the management of DTC.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18997044     DOI: 10.2967/jnumed.108.052399

Source DB:  PubMed          Journal:  J Nucl Med        ISSN: 0161-5505            Impact factor:   10.057


  31 in total

Review 1.  SPECT/CT and tumour imaging.

Authors:  Gad Abikhzer; Zohar Keidar
Journal:  Eur J Nucl Med Mol Imaging       Date:  2013-08-29       Impact factor: 9.236

2.  Endocrine radionuclide scintigraphy with fusion single photon emission computed tomography/computed tomography.

Authors:  Ka-Kit Wong; Arpit Gandhi; Benjamin L Viglianti; Lorraine M Fig; Domenico Rubello; Milton D Gross
Journal:  World J Radiol       Date:  2016-06-28

Review 3.  Clinical applications of 124I-PET/CT in patients with differentiated thyroid cancer.

Authors:  Lutz S Freudenberg; Walter Jentzen; Alexander Stahl; Andreas Bockisch; Sandra J Rosenbaum-Krumme
Journal:  Eur J Nucl Med Mol Imaging       Date:  2011-04-12       Impact factor: 9.236

Review 4.  A review on the clinical uses of SPECT/CT.

Authors:  Giuliano Mariani; Laura Bruselli; Torsten Kuwert; Edmund E Kim; Albert Flotats; Ora Israel; Maurizio Dondi; Naoyuki Watanabe
Journal:  Eur J Nucl Med Mol Imaging       Date:  2010-02-25       Impact factor: 9.236

5.  Gold nanorods for target selective SPECT/CT imaging and photothermal therapy in vivo.

Authors:  Boseung Jang; Seonhwa Park; Se Hun Kang; Joa Kyum Kim; Seok-Ki Kim; In-Hoo Kim; Yongdoo Choi
Journal:  Quant Imaging Med Surg       Date:  2012-03

6.  Combined SPECT and Multidetector CT for Prostate Cancer Evaluations.

Authors:  Carina Mari Aparici; David Carlson; Nhan Nguyen; Randall A Hawkins; Youngho Seo
Journal:  Am J Nucl Med Mol Imaging       Date:  2012

Review 7.  2015 American Thyroid Association Management Guidelines for Adult Patients with Thyroid Nodules and Differentiated Thyroid Cancer: The American Thyroid Association Guidelines Task Force on Thyroid Nodules and Differentiated Thyroid Cancer.

Authors:  Bryan R Haugen; Erik K Alexander; Keith C Bible; Gerard M Doherty; Susan J Mandel; Yuri E Nikiforov; Furio Pacini; Gregory W Randolph; Anna M Sawka; Martin Schlumberger; Kathryn G Schuff; Steven I Sherman; Julie Ann Sosa; David L Steward; R Michael Tuttle; Leonard Wartofsky
Journal:  Thyroid       Date:  2016-01       Impact factor: 6.568

Review 8.  Value of ¹³¹I SPECT/CT for the evaluation of differentiated thyroid cancer: a systematic review of the literature.

Authors:  Yan-Li Xue; Zhong-Ling Qiu; Hong-Jun Song; Quan-Yong Luo
Journal:  Eur J Nucl Med Mol Imaging       Date:  2012-12-15       Impact factor: 9.236

9.  Five months' follow-up of patients with and without iodine-positive lymph node metastases of thyroid carcinoma as disclosed by (131)I-SPECT/CT at the first radioablation.

Authors:  Daniela Schmidt; Rainer Linke; Michael Uder; Torsten Kuwert
Journal:  Eur J Nucl Med Mol Imaging       Date:  2009-11-20       Impact factor: 9.236

10.  Anatomic and metabolic imaging of venous thromboembolism mimicking thyroid carcinoma extension.

Authors:  Libo Chen; Yan Shen; Xiaohui Wu; Quanyong Luo
Journal:  J Thromb Thrombolysis       Date:  2010-04       Impact factor: 2.300

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.